Krystal Biotech Stock Analysis
KRYS Stock | USD 182.29 4.19 2.35% |
Krystal Biotech is overvalued with Real Value of 144.49 and Target Price of 150.44. The main objective of Krystal Biotech stock analysis is to determine its intrinsic value, which is an estimate of what Krystal Biotech is worth, separate from its market price. There are two main types of Krystal Biotech's stock analysis: fundamental analysis and technical analysis.
The Krystal Biotech stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Krystal Biotech is usually not traded on Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday. Krystal Stock trading window is adjusted to America/New York timezone.
Krystal |
Krystal Stock Analysis Notes
About 12.0% of the company outstanding shares are owned by corporate insiders. The company had not issued any dividends in recent years. Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania. Krystal Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 119 people. To find out more about Krystal Biotech contact the company at 412 586 5830 or learn more at https://www.krystalbio.com.Krystal Biotech Investment Alerts
Krystal Biotech generated a negative expected return over the last 90 days | |
Krystal Biotech currently holds about 425.56 M in cash with (88.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 16.58. | |
Krystal Biotech has a poor financial position based on the latest SEC disclosures | |
Over 88.0% of the company shares are owned by institutional investors | |
Latest headline from news.google.com: Segall Bryant Hamill LLC Boosts Stock Position in Krystal Biotech, Inc. - MarketBeat |
Krystal Biotech Upcoming and Recent Events
26th of February 2024 Upcoming Quarterly Report | View | |
13th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
26th of February 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Krystal Largest EPS Surprises
Earnings surprises can significantly impact Krystal Biotech's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2018-03-12 | 2017-12-31 | -0.23 | -0.26 | -0.03 | 13 | ||
2019-05-06 | 2019-03-31 | -0.33 | -0.29 | 0.04 | 12 | ||
2019-03-12 | 2018-12-31 | -0.23 | -0.27 | -0.04 | 17 |
Krystal Biotech Environmental, Social, and Governance (ESG) Scores
Krystal Biotech's ESG score is a quantitative measure that evaluates Krystal Biotech's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Krystal Biotech's operations that may have significant financial implications and affect Krystal Biotech's stock price as well as guide investors towards more socially responsible investments.
Krystal Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Hood River Capital Management Llc | 2024-09-30 | 502.1 K | Goldman Sachs Group Inc | 2024-06-30 | 422.3 K | Jennison Associates Llc | 2024-09-30 | 410.1 K | Lord, Abbett & Co Llc | 2024-06-30 | 392.2 K | Nuveen Asset Management, Llc | 2024-06-30 | 336.2 K | Woodline Partners Lp | 2024-06-30 | 291.9 K | Amvescap Plc. | 2024-06-30 | 275.1 K | Charles Schwab Investment Management Inc | 2024-09-30 | 240.2 K | Northern Trust Corp | 2024-09-30 | 238.7 K | Fmr Inc | 2024-09-30 | 4.3 M | Blackrock Inc | 2024-06-30 | 3.9 M |
Krystal Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 5.12 B.Krystal Profitablity
The company has Profit Margin (PM) of 0.22 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.42 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.42.Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.01 | 0.01 | |
Return On Capital Employed | (0.14) | (0.15) | |
Return On Assets | 0.01 | 0.01 | |
Return On Equity | 0.01 | 0.01 |
Management Efficiency
Krystal Biotech has return on total asset (ROA) of 0.0458 % which means that it generated a profit of $0.0458 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0638 %, meaning that it created $0.0638 on every $100 dollars invested by stockholders. Krystal Biotech's management efficiency ratios could be used to measure how well Krystal Biotech manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Krystal Biotech's Return On Tangible Assets are comparatively stable compared to the past year. Return On Assets is likely to gain to 0.01 in 2024, whereas Return On Capital Employed is likely to drop (0.15) in 2024. At this time, Krystal Biotech's Total Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 630.6 M in 2024, whereas Other Current Assets are likely to drop slightly above 4.2 M in 2024.Last Reported | Projected for Next Year | ||
Book Value Per Share | 28.67 | 30.11 | |
Tangible Book Value Per Share | 28.67 | 30.11 | |
Enterprise Value Over EBITDA | 168.59 | 177.02 | |
Price Book Value Ratio | 4.33 | 4.11 | |
Enterprise Value Multiple | 168.59 | 177.02 | |
Price Fair Value | 4.33 | 4.11 | |
Enterprise Value | 3 B | 3.2 B |
The strategic vision of Krystal Biotech management plays a critical role in its financial performance. By evaluating this vision, we provide insights into the stock's growth potential.
Operating Margin 0.4167 | Profit Margin 0.2168 | Beta 0.82 | Return On Assets 0.0458 | Return On Equity 0.0638 |
Technical Drivers
As of the 22nd of November, Krystal Biotech secures the Standard Deviation of 2.41, mean deviation of 1.75, and Risk Adjusted Performance of (0.04). Krystal Biotech technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices. Please verify Krystal Biotech risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and kurtosis to decide if Krystal Biotech is priced some-what accurately, providing market reflects its recent price of 182.29 per share. Given that Krystal Biotech has information ratio of (0.1), we recommend you to check Krystal Biotech's last-minute market performance to make sure the company can sustain itself at a future point.Krystal Biotech Price Movement Analysis
The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Krystal Biotech middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Krystal Biotech. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Krystal Biotech Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Krystal Biotech insiders, such as employees or executives, is commonly permitted as long as it does not rely on Krystal Biotech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Krystal Biotech insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Krystal Biotech Outstanding Bonds
Krystal Biotech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Krystal Biotech uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Krystal bonds can be classified according to their maturity, which is the date when Krystal Biotech has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Krystal Biotech Predictive Daily Indicators
Krystal Biotech intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Krystal Biotech stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Krystal Biotech Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 4th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 16th of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F4 | 13th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 28th of August 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 5th of August 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 10th of July 2024 An amended filing to the original Schedule 13G | ViewVerify |
Krystal Biotech Forecast Models
Krystal Biotech's time-series forecasting models are one of many Krystal Biotech's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Krystal Biotech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Krystal Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Krystal Biotech prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Krystal shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Krystal Biotech. By using and applying Krystal Stock analysis, traders can create a robust methodology for identifying Krystal entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | 0.23 | 0.24 | |
Operating Profit Margin | (1.95) | (2.05) | |
Net Profit Margin | 0.19 | 0.20 | |
Gross Profit Margin | 0.85 | 0.72 |
Current Krystal Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Krystal analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Krystal analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
150.44 | Strong Buy | 11 | Odds |
Most Krystal analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Krystal stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Krystal Biotech, talking to its executives and customers, or listening to Krystal conference calls.
Krystal Stock Analysis Indicators
Krystal Biotech stock analysis indicators help investors evaluate how Krystal Biotech stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Krystal Biotech shares will generate the highest return on investment. By understating and applying Krystal Biotech stock analysis, traders can identify Krystal Biotech position entry and exit signals to maximize returns.
Begin Period Cash Flow | 161.9 M | |
Common Stock Shares Outstanding | 27.8 M | |
Total Stockholder Equity | 778.6 M | |
Tax Provision | 2 M | |
Quarterly Earnings Growth Y O Y | -0.674 | |
Property Plant And Equipment Net | 168.2 M | |
Cash And Short Term Investments | 532.2 M | |
Cash | 358.3 M | |
Accounts Payable | 1.8 M | |
Net Debt | -350.2 M | |
50 Day M A | 180.448 | |
Total Current Liabilities | 33.1 M | |
Other Operating Expenses | 160.4 M | |
Non Current Assets Total | 230.4 M | |
Forward Price Earnings | 31.9489 | |
Non Currrent Assets Other | 263 K | |
Stock Based Compensation | 39.9 M |
Additional Tools for Krystal Stock Analysis
When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.